Corebridge Financial Inc. Has $811,000 Stock Position in Agios Pharmaceuticals, Inc. $AGIO

Corebridge Financial Inc. decreased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,688 shares of the biopharmaceutical company’s stock after selling 410 shares during the period. Corebridge Financial Inc.’s holdings in Agios Pharmaceuticals were worth $811,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Capital Fund Management S.A. acquired a new position in Agios Pharmaceuticals in the 1st quarter valued at approximately $2,118,000. Erste Asset Management GmbH grew its stake in shares of Agios Pharmaceuticals by 10.9% in the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company’s stock valued at $65,439,000 after purchasing an additional 220,000 shares during the period. Algert Global LLC grew its stake in shares of Agios Pharmaceuticals by 511.2% in the 1st quarter. Algert Global LLC now owns 74,810 shares of the biopharmaceutical company’s stock valued at $2,192,000 after purchasing an additional 62,570 shares during the period. American Century Companies Inc. grew its stake in shares of Agios Pharmaceuticals by 9.6% in the 1st quarter. American Century Companies Inc. now owns 114,947 shares of the biopharmaceutical company’s stock valued at $3,368,000 after purchasing an additional 10,110 shares during the period. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Agios Pharmaceuticals in the 1st quarter valued at approximately $256,000.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AGIO. Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 19th. Scotiabank lowered their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research note on Monday, July 28th. Bank of America lowered their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $56.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $36.01 on Friday. The firm has a market cap of $2.09 billion, a PE ratio of 3.27 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The stock’s 50 day simple moving average is $37.58 and its 200 day simple moving average is $33.21.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. As a group, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider James William Burns sold 2,799 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $93,878.46. Following the transaction, the insider directly owned 28,650 shares in the company, valued at approximately $960,921. This trade represents a 8.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sarah Gheuens sold 11,914 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the transaction, the insider owned 61,271 shares in the company, valued at $2,327,685.29. The trade was a 16.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 57,448 shares of company stock worth $2,026,141. Corporate insiders own 4.30% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.